On October 20, 2025, Disc Medicine, Inc. reported preliminary unaudited cash and marketable securities of approximately $615.9 million as of September 30, 2025, highlighting ongoing advancements in their hematology portfolio and upcoming business milestones for late 2025 and 2026.